ONKURE THERAPEUTICS INC-A (OKUR) Stock Price, Forecast & Analysis
USA - NASDAQ:OKUR - US68277Q1058 - Common Stock
OKUR Key Statistics, Chart & Performance
The current stock price of OKUR is 3.11 USD. In the past month the price increased by 9.69%. In the past year, price decreased by -80.9%.
OKUR Latest News, Press Relases and Analysis
OKUR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.56 | 410.00B | ||
| AMGN | AMGEN INC | 15.43 | 181.65B | ||
| GILD | GILEAD SCIENCES INC | 15.11 | 153.55B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 110.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.23 | 72.66B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 894.33 | 59.79B | ||
| INSM | INSMED INC | N/A | 40.96B | ||
| NTRA | NATERA INC | N/A | 28.70B | ||
| BIIB | BIOGEN INC | 9.57 | 23.48B | ||
| INCY | INCYTE CORP | 16.96 | 21.26B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.43 | 20.80B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.9 | 14.47B |
Related stock screener links
About OKUR
Company Profile
OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company is headquartered in Boulder, Colorado and currently employs 46 full-time employees. The company went IPO on 2021-04-09. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. The company is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. The company is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. The company is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. The company also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.
Company Info
ONKURE THERAPEUTICS INC-A
6707 Winchester Circle, Suite 400
Boulder COLORADO US
Employees: 46
Phone: 17203072892
ONKURE THERAPEUTICS INC-A / OKUR FAQ
Can you describe the business of ONKURE THERAPEUTICS INC-A?
OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company is headquartered in Boulder, Colorado and currently employs 46 full-time employees. The company went IPO on 2021-04-09. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. The company is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. The company is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. The company is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. The company also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.
Can you provide the latest stock price for ONKURE THERAPEUTICS INC-A?
The current stock price of OKUR is 3.11 USD. The price decreased by -1.89% in the last trading session.
What is the dividend status of ONKURE THERAPEUTICS INC-A?
OKUR does not pay a dividend.
What is the ChartMill rating of ONKURE THERAPEUTICS INC-A stock?
OKUR has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for ONKURE THERAPEUTICS INC-A?
ONKURE THERAPEUTICS INC-A (OKUR) has a market capitalization of 42.08M USD. This makes OKUR a Nano Cap stock.
What is the Short Interest ratio of ONKURE THERAPEUTICS INC-A (OKUR) stock?
The outstanding short interest for ONKURE THERAPEUTICS INC-A (OKUR) is 0.54% of its float.
OKUR Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to OKUR. When comparing the yearly performance of all stocks, OKUR is a bad performer in the overall market: 90.38% of all stocks are doing better.
OKUR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OKUR. OKUR has a great financial health rating, but its profitability evaluates not so good.
OKUR Financial Highlights
Over the last trailing twelve months OKUR reported a non-GAAP Earnings per Share(EPS) of -4.79. The EPS increased by 18.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -111.5% | ||
| ROE | -122.25% | ||
| Debt/Equity | 0 |
OKUR Forecast & Estimates
12 analysts have analysed OKUR and the average price target is 30.6 USD. This implies a price increase of 883.92% is expected in the next year compared to the current price of 3.11.